%0 Journal Article %A Lia Humphrey %A Edward W. Thommes %A Roie Fields %A Naseem Hakim %A Ayman Chit %A Monica G. Cojocaru %T A path out of COVID-19 quarantine: an analysis of policy scenarios %D 2020 %R 10.1101/2020.04.23.20077503 %J medRxiv %P 2020.04.23.20077503 %X In this work we present an analysis of the two major strategies currently implemented around the world in the fight against COVID-19: Social distancing & shelter-in-place measures to protect the susceptible, and testing & contact-tracing to identify, isolate and treat the infected. The majority of countries have principally relied on the former; we consider the examples of Italy, Canada and the United States. By fitting a disease transmission model to daily case report data, we infer that in each of the three countries, the current level of national shutdown is equivalent to about half the population being under quarantine. We demonstrate that in the absence of other measures, scaling back social distancing in such a way as to prevent a second wave will take prohibitively long. In contrast, South Korea, a country that has managed to control and suppress its outbreak principally through mass testing and contact tracing, and has only instated a partial shutdown. For all four countries, we estimate the level of testing which would be required to allow a complete exit from shutdown and a full lifting of social distancing measures, without a resurgence of COVID-19. We find that a “brute-force” approach of untargeted universal testing requires an average testing rate of once every 36 to 48 hours for every individual, depending on the country. If testing is combined with contact tracing, and/or if tests are able to identify latent infection, then an average rate of once every 4 to 5 days is sufficient.Significance Statement We demonstrate how current quarantine measures can be lifted after the current pandemic wave by large-scale, frequent-testing and contact tracing on the remaining susceptible populations. We present an analysis of the two major strategies currently implemented around the world against COVID-19: Social distancing & shelter-in-place measures to protect the susceptible, and testing & contact-tracing to identify, isolate and treat the infected. We find that a “brute-force” approach of untargeted universal testing requires an average testing rate of once every 36 to 48 hours for every individual, depending on the country. If testing is combined with contact tracing, and/or if tests are able to identify latent infection, then an average rate of once every 4 to 5 days is sufficient.Competing Interest StatementEdward W. Thommes and Ayman Chit are employees of Sanofi Pasteur. Monica G. Cojocaru has received national research grants (NSERC CANADA) in the past, in which Sanofi Pasteur was a matching partner, however none of the work here was supported by those grants.Funding StatementNo third party payments have been received for this work. M. G. Cojocaru, L. Humphrey and R. Fields acknowledge support from the National Science and Engineering Research Council of Canada, Discovery Grant 400684 (PI: Cojocaru).Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data is from publicly available sources. %U https://www.medrxiv.org/content/medrxiv/early/2020/04/29/2020.04.23.20077503.full.pdf